Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6079)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jan 24, 2021 (publication date) through Nov 21, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Henriquez I, Spratt D, Gómez-Iturriaga A, Abuchaibe O, Couñago F. Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease. World J Clin Oncol 2021; 12(1): 6-12 [PMID: 33552935 DOI: 10.5306/wjco.v12.i1.6] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v12/i1/6.htm |
| Number | Citing Articles |
| 1 |
Brendan A. Yanada, David Homewood, Brendan H. Dias, Cindy Ogluszko, Niall M. Corcoran. The treatment landscape of nonmetastatic castrate resistant prostate cancer: A contemporary perspective. Urologic Oncology: Seminars and Original Investigations 2024; 42(6): 175.e9 doi: 10.1016/j.urolonc.2024.03.005
|
| 2 |
Umang Swami, Agnes Hong, Brandon Diessner, Christopher Young, Scott H Bunner, Bin Xie, Krishnan Ramaswamy, Benjamin Chastek, Nader El Chaar, Sumati Gupta. Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States. Future Oncology 2024; 20(32): 2467 doi: 10.1080/14796694.2024.2373681
|
| 3 |
Virginia Fernandez, Yasamin Mirzabeigi, Andrew M. Joseph, Monica Karas, Jenelle Grandison, Michael Rejzer, Samantha Gogola. Therapy Resistance in Prostate Cancer. 2024; : 289 doi: 10.1016/B978-0-443-16032-5.00009-9
|
| 4 |
Kazuhiro Matsumoto, Takeo Kosaka, Toshikazu Takeda, Keishiro Fukumoto, Yota Yasumizu, Nobuyuki Tanaka, Shinya Morita, Ryuichi Mizuno, Hiroshi Asanuma, Mototsugu Oya. Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI). International Journal of Clinical Oncology 2024; 29(8): 1198 doi: 10.1007/s10147-024-02549-5
|
| 5 |
David Conde-Estévez, Iván Henríquez, Jesús Muñoz-Rodríguez, Alejo Rodriguez-Vida. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions. Expert Opinion on Drug Metabolism & Toxicology 2022; 18(9): 601 doi: 10.1080/17425255.2022.2122812
|
| 6 |
Iván Henríquez, Mack Roach, Todd M. Morgan, Alberto Bossi, Junior A. Gómez, Oscar Abuchaibe, Felipe Couñago. Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC). Biomedicines 2021; 9(9): 1247 doi: 10.3390/biomedicines9091247
|